1. Postmarketing surveillance of enalapril: experience in 11710 hypertensive patients in general practice;Cooper, W.D.; Sheldon, D.; Brown, D.; Kimber, G.R.; Isitt, V.L.; Currie, W.J.C.;J R Coll Gen Pract,1987
2. Wifton LV._Postmarketing surveillance of enalapril. II: Investigation of the role of enalapril in deaths with renal failure;Speirs, C.J.; Dollery, C.T.; Inman, W.H.W.; Rawson, N.S.B.;BrMedJ7
3. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors;DiBianco, R.;Medical Toxicology,1986
4. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril;Irvin, J.D.; Viau, J.M.;AmJ Med,1986
5. Review of the overall experience of captopril in hypertension;Frohlich, E.D.; Cooper, R.A.; Lewis, E.J.;Arch Intern Med,1984